Waystar Holding (WAY) is back in focus after second quarter 2026 results, a higher full year revenue outlook, and fresh commentary on AI driven solutions and cross sell activity following the Iodine acquisition.

Despite strong Q2 results and higher guidance, Waystar Holding’s recent trading has been weak. The share price is US$21.11, with a year-to-date share price return down 32.71% and a 1-year total shareholder return down 40.69%. This points to fading momentum and a more cautious risk assessment from the market.

If you like the AI angle in healthcare but want a broader watchlist, take a look at our screener of 41 healthcare AI stocks

Waystar Holding has lifted its outlook, yet the stock is still well below where it started the year. Has most of the easy repricing already happened, or is there meaningful upside still on the table once you look at valuation next?

Most Popular Narrative: 37.6% Undervalued

Waystar Holding’s most widely followed narrative sees fair value at $33.83, well above the last close of $21.11. This frames a sizable valuation gap for investors to interrogate.

The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, will expand Waystar's total addressable market by over 15%, accelerate its product roadmap, and immediately boost gross margins and adjusted EBITDA margins, setting up compounding, long-term revenue and earnings growth.

Want to see what sits behind that confidence in Waystar Holding? The narrative leans heavily on faster revenue growth, higher margins and a richer earnings multiple. Curious which specific assumptions connect those dots into a $33.83 fair value?

Result: Fair Value of $33.83 (UNDERVALUED)

However, the bullish Waystar Holding narrative still faces real pressure points, including higher leverage from the US$1.25b Iodine deal and rising competition in AI driven RCM tools.

Another View on Waystar Holding’s Valuation

The SWS DCF model points to a fair value of $45.32 for Waystar Holding, which is much higher than the current share price of $21.11. That suggests the stock may be undervalued, yet it currently trades on a P/E of 30x, above the global Healthcare Services average of 26.2x. How comfortable are you with those mixed signals?

Next Steps

Reading this, you can see why opinions on Waystar Holding are divided, yet optimism around certain rewards is still clear. Act while the data is fresh and decide where you stand by reviewing the 3 key rewards

Looking for more investment ideas beyond Waystar Holding?

You have seen how nuanced Waystar Holding looks right now. Do not stop there when you can quickly scan other opportunities that might fit your style.

• Target potential mispricing by checking companies that screen as 55 high quality undervalued stocks and see which ones line up with your return expectations.
• Prioritise resilience by reviewing 81 resilient stocks with low risk scores and focus on stocks where the risk profile may better match your tolerance.
• Get ahead of the crowd by scanning our screener containing 19 high quality undiscovered gems before attention turns to them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.